Abstract:The molecular mechanisms exploration of anti‐cancer effects of luteolin, in‐depth investigation with regard to pharmacokinetic properties and drug delivery systems, will enormously facilitate the benefits for clinical patients. Current pharmaceutical research is energetically excavating the pharmacotherapeutic role of herb‐derived ingredients in multiple malignancies' targeting. Luteolin is one of the major phytochemical components that exist in various traditional Chinese medicine or medical herbs. Mounting evidence reveals that this phytoconstituent endows prominent therapeutic actions on diverse malignancies, with the underlying mechanisms, combined medication strategy, and pharmacokinetics elusive. Additionally, the clinical trial and pharmaceutical investigation of luteolin remain to be systematically delineated. The present review aimed to comprehensively summarize the updated information with regard to the anticancer mechanism, combined medication strategies, pharmacokinetics, clinical trials, and pharmaceutical researches of luteolin. The survey corroborates that luteolin executes multiple anticancer effects mainly by dampening proliferation and invasion, spurring apoptosis, intercepting cell cycle, regulating autophagy and immune, inhibiting inflammatory response, inducing ferroptosis, and pyroptosis, as well as epigenetic modification, and so on. Luteolin can be applied in combination with numerous clinical anticarcinogens and natural ingredients to synergistically enhance the therapeutic efficacy of malignancies while reducing adverse reactions. For pharmacokinetics, luteolin has an unfavorable oral bioavailability, it mainly persists in plasma as glucuronides and sulfate‐conjugates after being metabolized, and is regarded as potent inhibitors of OATP1B1 and OATP2B1, which may be messed with the pharmacokinetic interactions of miscellaneous bioactive substances in vivo. Besides, pharmaceutical innovation of luteolin with leading‐edge drug delivery systems such as host–guest complexes, nanoparticles, liposomes, nanoemulsion, microspheres, and hydrogels are beneficial to the exploitation of luteolin‐based products. Moreover, some registered clinical trials on luteolin are being carried out, yet clinical research on anticancer effects should be continuously promoted.

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors

Effect of Luteolin and its combination with chemotherapeutic drugs on cytotoxicity of cancer cells]

Luteolin suppresses growth and migration of human lung cancer cells

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.

Anti-proliferation Activity of Luteolin and Its Role in Combined Chemotherapy on Lung Cancer A549 Cells

Research progress on anti-tumor effects of luteolin]

Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments

Anti-proliferative and Chemosensitizing Effects of Luteolin on Human Gastric Cancer AGS Cell Line

Luteolin Inhibits Lung Cancer Cell Migration by Negatively Regulating TWIST1 and MMP2 Through Upregulation of miR-106a-5p

Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches

Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs

Identification of the Key Active Pharmaceutical Ingredients of Yishen Qutong Granule, A Chinese Medicine Formula, in the Treatment of Primary Lung Cancer.

Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis

Luteolin Reduces Aqueous Extract PM2.5-induced Metastatic Activity in H460 Lung Cancer Cells

Luteolin inhibited proliferation and induced apoptosis of prostate cancer cells through miR-301.

Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells

Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC

Luteolin Enhances Tnf-Related Apoptosis-Inducing Ligand'S Anticancer Activity in A Lung Cancer Xenograft Mouse Model

Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy

Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non‐small cell lung cancer